Robert L. Quigley, MD, DPhil, is the Senior Vice President and Global Medical Director, Corporate Health Solutions atInternational SOS&MedAire. After 25 years working in surgery, critical care, and immunology, he’s using his expertise to advise on crisis management, infectious disease, and health care. Here, he shares what people in the U.S. should know about the Delta variant.
The Delta Variant May Cause Different COVID-19 Symptoms
As scientists learn more about how the COVID-19 virus mutates and spreads, here are three things you should know about the Delta variant.
Delta Variant Is Creating a Web of Regional COVID-19 Epidemics
Delta Seems More Easily Transmissible and Harder to Combat
The way the Delta variant has mutated has caused the surface of the virus to change, which can affect how the virus attaches to other cells. This means that it may be more difficult for existing antibodies, whether from previous COVID-19 infection or vaccination, to tightly bind to the virus and effectively neutralize the new infection.
Similarly, drugs designed to treat COVID-19 infection can be less effective at fighting this variant. The Delta variant’s mutated surface has the potential to allow the virus to tightly attach to target receptors in the body, which is what makes the virus highly contagious.
Complete Vaccination Is Essential
Research suggests those who are fully vaccinated are not as protected against the Delta variant as they may be against other strains of COVID-19.
Specifically, recent reports indicate that following the two doses of the Pfizer and AstraZeneca vaccines, recipients were respectively afforded 88% and 66% protection against symptomatic disease from the Delta variant.These results represent a slight decrease in efficacy when compared to rates seen with the less fatal variants, like the Alpha variant.
However, a single dose of either vaccine was only 33% effective at protecting people from symptomatic disease from the Delta variant.One study found that people who received only one of the two recommended doses for the AstraZeneca and Pfizer vaccines had antibody responses that “barely inhibited variant Delta.”
There is a growing concern that this variant may be responsible forbreakthrough infectionin fully-vaccinated people. Still, a two-dose regimen offers significantly better protection than partial or no vaccination.
Young People Are Taking the Biggest Hit
The Delta variant appears to be disproportionately spreading in people 12–20 years old.But thanks to theMay authorizationof the Pfizer vaccine in ages 12-15, this group can now be protected.
Obviously, that still leaves an exposed population: children under 12 years of age. We all are patiently awaiting the results ofrandomized placebo studiesinvolving children younger than 12 to determine both the safety and efficacy of the vaccines in this group.
The prudent way to combat the Delta variant, and any other strains of COVID-19, is through vaccination. The message is simple: Get fully vaccinated against this evolving virus. It will help protect those who can’t yet.
The information in this article is current as of the date listed, which means newer information may be available when you read this. For the most recent updates on COVID-19, visit ourcoronavirus news page.
7 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
Centers for Disease Control and Prevention.COVID data tracker: variant proportions.
Public Health England.SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 16.
World Health Organization.COVID-19 virtual press conference transcript.
Bernal JL, Andrews N, Gower C, et al.Effectiveness of COVID-19 vaccines against the B.1.617.2 variant.medRxiv. Preprint posted online May 24, 2021. doi:10.1101/2021.05.22.21257658
The Pharmaceutical Journal.Everything you need to know about COVID-19 vaccines.
Planas D, Veyer D, Baidaliuk A, et al.Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.Nature. Published online July 8, 2021. doi:10.1038/s41586-021-03777-9
Meet Our Medical Expert Board
Share Feedback
Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit
Was this page helpful?
Thanks for your feedback!
What is your feedback?OtherHelpfulReport an ErrorSubmit
What is your feedback?